In an attempt to inhibit fast actin remodeling in CLL cells during NK cell attack and to confirm the causal relation between the AR and CLL cell-intrinsic resistance to NK cell-mediated lysis, CDC42 was pharmacologically inhibited using the cell-permeable CDC42-specific inhibitor ZCL278 (56). Here, CDC42 is linked to B-cell chronic lymphocytic leukemia.